Uveal melanoma (UM) is the most common primary intraocular cancer in adults.1,2 Unlike cutaneous melanoma, which metastasizes to local lymph nodes, UM spreads hematogenously, with the most common site of initial metastasis being the liver.1 Forty percent of patients develop metastases within 10 years of diagnosis,3 and mean survival ranges from 2 to 12.5 months after metastasis.4,5 The best current treatment, with either chemotherapy or immunotherapy, only extends survival for metastatic disease by a couple of months.1 Overall, the prognosis is grim, with few good treatment options available.
Daniels AB, Abramson DH. c-KIT in Uveal MelanomaBig Fish or Red Herring?. Arch Ophthalmol. 2009;127(5):695-697. doi:10.1001/archophthalmol.2009.49